CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade OXFORD BIOMEDICA PLC ORD 50P - OXB CFD

4.240
1.45%
Market Trading Hours* (UTC) Open now
Closes on Wednesday at 16:30

Mon - Fri: 08:00 - 16:30

  • Summary
  • Historical Data
Trading сonditions
Spread 0.070
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023925 %
Charges from full value of position ($-4.55)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023925%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002007 %
Charges from full value of position ($0.38)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002007%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency GBP
Margin 5.00%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

Key Stats
Prev. Close 4.13
Open 4.15
1-Year Change 112.28%
Day's Range 4.15 - 4.25
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 4.130 0.010 0.24% 4.120 4.235 4.120
Dec 16, 2024 4.165 0.080 1.96% 4.085 4.275 4.085
Dec 13, 2024 4.245 0.020 0.47% 4.225 4.285 4.020
Dec 12, 2024 4.215 -0.080 -1.86% 4.295 4.310 4.215
Dec 11, 2024 4.215 -0.035 -0.82% 4.250 4.310 4.195
Dec 10, 2024 4.215 0.045 1.08% 4.170 4.315 4.170
Dec 9, 2024 4.195 -0.010 -0.24% 4.205 4.340 4.155
Dec 6, 2024 4.165 -0.005 -0.12% 4.170 4.295 4.165
Dec 5, 2024 4.170 0.050 1.21% 4.120 4.250 4.120
Dec 4, 2024 4.170 -0.060 -1.42% 4.230 4.285 4.105
Dec 3, 2024 4.195 -0.035 -0.83% 4.230 4.345 4.180
Dec 2, 2024 4.165 -0.035 -0.83% 4.200 4.260 4.115
Nov 29, 2024 4.190 0.020 0.48% 4.170 4.265 4.165
Nov 28, 2024 4.195 0.045 1.08% 4.150 4.270 4.150
Nov 27, 2024 4.180 0.030 0.72% 4.150 4.260 4.075
Nov 26, 2024 4.135 -0.015 -0.36% 4.150 4.230 4.100
Nov 25, 2024 4.235 0.140 3.42% 4.095 4.245 4.040
Nov 22, 2024 4.100 0.140 3.54% 3.960 4.200 3.960
Nov 21, 2024 4.040 0.115 2.93% 3.925 4.150 3.925
Nov 20, 2024 4.045 0.025 0.62% 4.020 4.135 4.020

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Oxford BioMedica plc Company profile

About Oxford BioMedica plc

Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Financial summary

BRIEF: For the six months ended 30 June 2021, Oxford BioMedica plc revenues increased from £34M to £81.3M. Net income totaled £18.1M vs. loss of £6.7M. Revenues reflect Europe segment increase from £19M to £70.3M. Net Income reflects Platform segment income totaling £24.4M vs. loss of £3.1M. Basic Earnings per Share excluding Extraordinary Items increased from -£0.09 to £0.22.

Equity composition

10/2003, Rights Issue, 27 new shs for every 50 shs held @ GBP 0.17 (Fct:1.54). 03/2001, Rights Issue, 1 new share for every 9 shs held @ GBP 0.55 (Fct:1.111111). 03/1998, Rights Issue, 1 new share for every 4 shs held @ GBP 0.10 (Fct:1.076). 05/2014, Priority Issue, 1 new shares for every 5 shares held @ GBp 2 (Factor:1).

Industry: Bio Therapeutic Drugs

Windrush Court
Transport Way
OXFORD
OXFORDSHIRE OX4 6LT
GB

People also watch

ETH/USD

3,876.25 Price
-1.380% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

US100

22,073.10 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

2.57 Price
-1.620% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01280

BTC/USD

105,147.10 Price
-1.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading